hackint0sh/temp-data huggingface dataset:
protocolSection identificationModule nctId: NCT06337981, orgStudyIdInfo id: 21DE20901, briefTitle: Efficacy and Safety of AJU-S56 in Dry Eye Syndrome Patients, statusModule overallStatus: COMPLETED, startDateStruct date: 2021-11-22, primaryCompletionDateStruct date: 2022-06-14, completionDateStruct date: 2022-11-28, studyFirstPostDateStruct date: 2024-03-29, lastUpdatePostDateStruct date: 2024-04-29, sponsorCollaboratorsModule leadSponsor name: AJU Pharm Co., Ltd., class: INDUSTRY, collaborators name: GL Pharm Tech Corporation, descriptionModule briefSummary: This study is planned to Evaluate the Efficacy and Safety of test drug (AJU-S56) compared to control drug(vehicle) in Patients with Dry Eye Disease., conditionsModule conditions: Dry Eye Syndromes, designModule studyType: INTERVENTIONAL, phases: PHASE2, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: QUADRUPLE, whoMasked: PARTICIPANT, whoMasked: CARE_PROVIDER, whoMasked: INVESTIGATOR, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 99, type: ACTUAL, armsInterventionsModule interventions name: (AJU-S56 5% and placebo), interventions name: AJU-S56 5%, interventions name: Placebo(Vehicle), outcomesModule primaryOutcomes measure: Total corneal staining score (TCSS), secondaryOutcomes measure: LGCSS, secondaryOutcomes measure: TFBUT, eligibilityModule sex: ALL, minimumAge: 19 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: AJU Pharm Co., Ltd., city: Seoul, country: Korea, Republic of, geoPoint lat: 37.566, lon: 126.9784, hasResults: False
protocolSection identificationModule nctId: NCT06337968, orgStudyIdInfo id: Circum-Psoas Block LN, briefTitle: CPB for Arthroscopic Hip Surgery, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05-01, primaryCompletionDateStruct date: 2025-04-30, completionDateStruct date: 2025-05-31, studyFirstPostDateStruct date: 2024-03-29, lastUpdatePostDateStruct date: 2024-04-19, sponsorCollaboratorsModule leadSponsor name: The Second Hospital of Shandong University, class: OTHER, descriptionModule briefSummary: Arthroscopic hip surgery is being increasingly performed to treat both intraarticular and extraarticular hip diseases. Despite the minimally invasive approach, patients undergoing arthroscopic hip surgery still suffer severe pain due to the complex nature of hip innervation. Postoperative pain reduces patient satisfaction and delay patient recovery and discharge. The efficacy of regional anesthesia techniques in postoperative pain management have been proved in various surgeries. However, it remains controversial whether or not peripheral nerve blocks can significantly improve postoperative analgesia after hip arthroscopy.Several studies have shown that the fascia iliac block cannot improve postoperative analgesia for hip arthroscopy because it blocks only some branches of the lumbar plexus but not the sacral plexus. Circum-Psoas Block (CPB) which has been defined in recent years is able to block the lumbar plexus nerves as well as sacral plexus such as the sciatic, superior gluteal, and inferior gluteal nerves. Therefore, the investigators predict that it can provide effective postoperative analgesia for hip arthroscopy. In this study, the researchers aim to investigate the effectiveness of CPB in hip arthroscopy., conditionsModule conditions: Acute Pain, conditions: Opioid Use, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: TRIPLE, whoMasked: PARTICIPANT, whoMasked: INVESTIGATOR, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 74, type: ESTIMATED, armsInterventionsModule interventions name: Circum-psoas Block, interventions name: Sham block, outcomesModule primaryOutcomes measure: pain severity at 6 hours postoperatively, secondaryOutcomes measure: Postoperative opioid consumption, secondaryOutcomes measure: Postoperative nausea and vomiting, secondaryOutcomes measure: neurologic evaluation, secondaryOutcomes measure: Patient satisfaction, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 70 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06337955, orgStudyIdInfo id: 20170007596, briefTitle: Non Primary HCMV Infection: Natural History and Immune Response, statusModule overallStatus: ACTIVE_NOT_RECRUITING, startDateStruct date: 2017-06-06, primaryCompletionDateStruct date: 2024-09, completionDateStruct date: 2024-12, studyFirstPostDateStruct date: 2024-03-29, lastUpdatePostDateStruct date: 2024-04-01, sponsorCollaboratorsModule leadSponsor name: Foundation IRCCS San Matteo Hospital, class: OTHER, collaborators name: Università degli Studi di Pavia, collaborators name: Merck Sharp & Dohme LLC, collaborators name: Fondazione Regionale per la Ricerca Biomedica (FRRB) - Regione Lombardia, descriptionModule briefSummary: The goals of this observational study are: i) investigate the natural history of non-primary (i.e. reactivation and reinfection) HCMV infection in HCMV-seropositive Italian women and the relevant humoral and cell-mediated immune response; ii) reliably distinguish between reactivation and reinfection.Prerequisite of the study is the availability of a maternal HCMV strain at baseline (original strain) to which subsequent strains detected during follow-up are compared in order to distinguish between reactivation (original strain) or reinfection (new strain).To increase the likelihood of exposure to different HCMV strains, the study population is restricted to mothers of children attending day care centers., conditionsModule conditions: Cytomegalovirus Infections, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 204, type: ACTUAL, outcomesModule primaryOutcomes measure: HCMV non-primary infection (reinfection or reactivation)., secondaryOutcomes measure: HCMV-specific humoral and cell-mediated immune response during non-primary infection., secondaryOutcomes measure: Maternal behaviours and occurrence of non-primary infection, otherOutcomes measure: Potential use of saliva swabs for antibody determination., eligibilityModule sex: FEMALE, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Fondazione IRCCS Policlinico San Matteo, city: Pavia, state: PV, zip: 27100, country: Italy, geoPoint lat: 45.19205, lon: 9.15917, hasResults: False
protocolSection identificationModule nctId: NCT06337942, orgStudyIdInfo id: 23-001621, briefTitle: Deceased Donor Bladder or Combined Kidney-bladder Transplantation: a Phase 0 First-in-human Study, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-04-01, primaryCompletionDateStruct date: 2025-04, completionDateStruct date: 2027-04, studyFirstPostDateStruct date: 2024-03-29, lastUpdatePostDateStruct date: 2024-03-29, sponsorCollaboratorsModule leadSponsor name: University of California, Los Angeles, class: OTHER, descriptionModule briefSummary: The goal of this clinical trial is to demonstrate the feasibility of bladder transplantation in patients with terminal bladder diseases who would benefit from a new bladder or a combined kidney and bladder transplant. The main questions it aims to answer are:* Is human bladder transplantation feasible and safe?* How will the new bladder function in terms of storage and emptying?Participants will undergo a bladder-only or combined kidney and bladder transplantation. They will then be followed for two years to evaluate the efficacy, safety, and functionality of the bladder transplant., conditionsModule conditions: Bladder Disease, conditions: Bladder, Neurogenic, conditions: Bladder Cancer, conditions: Kidney Failure, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NON_RANDOMIZED, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 5, type: ESTIMATED, armsInterventionsModule interventions name: Bladder Transplantation, interventions name: Combined Kidney and Bladder Transplantation, outcomesModule primaryOutcomes measure: Demonstrating the technical success of bladder or combined kidney-bladder transplantation, secondaryOutcomes measure: Incidence of adverse events after bladder or combined kidney-bladder transplantation, secondaryOutcomes measure: Incidence of immune rejection after bladder or combined kidney-bladder transplantation, secondaryOutcomes measure: Evaluate the functionality of the transplanted bladder, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 70 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: UCLA, status: RECRUITING, city: Los Angeles, state: California, zip: 90095, country: United States, contacts name: Magdalena Mendez-Smith, role: CONTACT, phone: 310-267-7727, email: mmendezsmith@mednet.ucla.edu, contacts name: Nima Nassiri, MD, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 34.05223, lon: -118.24368, hasResults: False
protocolSection identificationModule nctId: NCT06337903, orgStudyIdInfo id: Self-compassion for PwMS, briefTitle: Self-compassion for People With Multiple Sclerosis: An Exploratory Feasibility Study, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05-01, primaryCompletionDateStruct date: 2025-04-30, completionDateStruct date: 2025-04-30, studyFirstPostDateStruct date: 2024-03-29, lastUpdatePostDateStruct date: 2024-04-01, sponsorCollaboratorsModule leadSponsor name: Robert Simpson, class: OTHER, descriptionModule briefSummary: The goal of this clinical trial is to develop and investigate a compassion-based intervention (Mindful Self-Compassion course) in people with multiple sclerosis. The main objectives are:1. Explore feasibility of trial processes including recruitment, adherence, retention, and follow-up2. Explore experiences of people with multiple sclerosis with the Compassion-based intervention, including perceived effects, barriers and facilitators to participation, suggestions for improvement3. Determine potential effects on stress, anxiety, depression, emotion regulation, illness adjustment, and self-compassion.Participants will be asked to take part in an 8-week online Mindful Self-Compassion course and report changes in levels of stress, anxiety, depression, self-compassion, adjustment, emotion, and quality of life from pre- to post-intervention and at 3-month follow-up. Additionally, participants will be asked to take part in a semi-structured interview to explore their experiences with the course, perceived effects, and suggestions for improvement., conditionsModule conditions: Multiple Sclerosis, conditions: Self-Compassion, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: HEALTH_SERVICES_RESEARCH, maskingInfo masking: NONE, enrollmentInfo count: 45, type: ESTIMATED, armsInterventionsModule interventions name: Self-compassion intervention (the Mindful Self-Compassion course), outcomesModule primaryOutcomes measure: Recruitment, primaryOutcomes measure: Retention, primaryOutcomes measure: Adherence, primaryOutcomes measure: Follow-up rates, secondaryOutcomes measure: Stress, secondaryOutcomes measure: Anxiety, secondaryOutcomes measure: Depression, secondaryOutcomes measure: Self-compassion, secondaryOutcomes measure: Emotion Regulation, secondaryOutcomes measure: Quality of Life using the Multiple Sclerosis Impact Scale (MSIS-29), secondaryOutcomes measure: Participant Experiences and Perspectives, secondaryOutcomes measure: Adjustment, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Unity Health Toronto, city: Toronto, country: Canada, contacts name: Robert Simpson, PhD, role: CONTACT, geoPoint lat: 43.70011, lon: -79.4163, hasResults: False
protocolSection identificationModule nctId: NCT06337890, orgStudyIdInfo id: FEZECO, briefTitle: CO2 Automated Angiographies With Fusion Imaging for Zero- or Near Zero- Contrast FEVAR., statusModule overallStatus: RECRUITING, startDateStruct date: 2024-01-01, primaryCompletionDateStruct date: 2024-12-31, completionDateStruct date: 2024-12-31, studyFirstPostDateStruct date: 2024-03-29, lastUpdatePostDateStruct date: 2024-03-29, sponsorCollaboratorsModule leadSponsor name: University of Bologna, class: OTHER, descriptionModule briefSummary: Fenestrated endovascular aneurysm repair (FEVAR) is an established technique used to treat complex aortic aneurysms (TAAAs), with satisfactory early and midterm results.Postoperative renal function worsening is a common adverse event after FEVAR of complex aneurysms and is associated with prolonged hospital stay, higher morbidity, and long-term mortality in the peri-operative period and during follow-up. One of the more common causes of renal function worsening is contrast-induced nephropathy resulting from the use of iodinated contrast medium (ICM).Automated carbon dioxide (CO2) angiography has been proposed as an alternative to ICM for standard endovascular aneurysm repair (EVAR) in consideration of its absence of nephrotoxicity that can be of further help in preserving renal function.In adjunct, hybrid room and fusion imaging (FI) technologies are useful tools to reduce intraoperative contrast medium and fluoroscopy time.In literature there are few reports regarding the use of CO2 for fenestrated endografting repair of complex aortic aneurysms.The aim of the present study is to report the possibility to combine the use of automated CO2 angiographies and Fusion Imaging to obtain zero- or near zero- contrast FEVAR for complex aortic aneurysms., conditionsModule conditions: Aortic Aneurysm, designModule studyType: OBSERVATIONAL, designInfo observationalModel: CASE_CONTROL, timePerspective: PROSPECTIVE, enrollmentInfo count: 40, type: ESTIMATED, armsInterventionsModule interventions name: Zero contrast FEVAR, outcomesModule primaryOutcomes measure: Rate of technical success, primaryOutcomes measure: Reintervention and mortality, primaryOutcomes measure: Number of participants with perioperative renal function worsening, primaryOutcomes measure: Rate of TVVs instability, primaryOutcomes measure: Rate of survival, primaryOutcomes measure: Rate of reintervention, primaryOutcomes measure: Number of participants with renal function worsening, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 99 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: University of Bologna, status: RECRUITING, city: Bologna, state: Emilia Romagna, zip: 40138, country: Italy, contacts name: Enrico Gallitto, MD, PhD, role: CONTACT, phone: +390512143288, email: enrico.gallitto@gmail.com, geoPoint lat: 44.49381, lon: 11.33875, hasResults: False
protocolSection identificationModule nctId: NCT06337877, orgStudyIdInfo id: pEEG ARDS, briefTitle: Assessment of Sedation Depth in ARDS Patients Undergoing Therapeutic Paralysis, statusModule overallStatus: ACTIVE_NOT_RECRUITING, startDateStruct date: 2023-10-01, primaryCompletionDateStruct date: 2024-04-17, completionDateStruct date: 2024-04-24, studyFirstPostDateStruct date: 2024-03-29, lastUpdatePostDateStruct date: 2024-03-29, sponsorCollaboratorsModule leadSponsor name: Tepecik Training and Research Hospital, class: OTHER, descriptionModule briefSummary: "In intensive care units, therapeutic paralysis has been a routine treatment method for many years in a select group of patients. Sufficient and appropriate sedation in patients undergoing therapeutic paralysis is crucial to prevent awareness and reduce the risk of excessive sedation. Both inadequate and excessive sedation levels can be highly detrimental to the patient. Clinical assessment may not always provide accurate information regarding sedation depth. Recently, the frequency and workload of therapeutic paralysis treatment in intensive care units have increased due to COVID-19 pneumonia. Therefore, the investigators believe that inadequate sedation may be common in these patients. Processed electroencephalogram parameters such as bispectral index or patient state index (PSI), routinely used in operating rooms and intensive care units, are commonly used to indicate sedation depth. In this study, the investigators aimed to determine sedation levels in patients during paralysis, assess the prevalence of inadequate or excessive sedation, and observe the doses of sedatives and analgesics used.", conditionsModule conditions: Sedation Complication, conditions: Acute Respiratory Distress Syndrome Due to COVID-19, conditions: Anesthesia Awareness, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 52, type: ACTUAL, armsInterventionsModule interventions name: Depth of sedation monitoring, outcomesModule primaryOutcomes measure: To determine the sedation levels of patients during paralysis, primaryOutcomes measure: The prevalence of inadequate or excessive sedation,, secondaryOutcomes measure: Evaluation of Concordance Between Richmond Agitation-Sedation Scale (RASS),, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Aykut Saritaş, city: İ̇zmi̇r, zip: 35640, country: Turkey, geoPoint lat: 38.41273, lon: 27.13838, hasResults: False
protocolSection identificationModule nctId: NCT06337825, orgStudyIdInfo id: 22-727, briefTitle: Object Assessment of Improvement in Non-Specific Symptoms After Parathyroidectomy for Primary Hyperparathyroidism, statusModule overallStatus: ACTIVE_NOT_RECRUITING, startDateStruct date: 2022-07-19, primaryCompletionDateStruct date: 2024-03-12, completionDateStruct date: 2024-06-29, studyFirstPostDateStruct date: 2024-03-29, lastUpdatePostDateStruct date: 2024-04-15, sponsorCollaboratorsModule leadSponsor name: The Cleveland Clinic, class: OTHER, descriptionModule briefSummary: Wearable electronic devices are becoming more prevalent in daily life, as they offer real time information on physiological parameters such as heart rate, activity level, oxygenation, and sleep patterns for their users. These wearable electronic devices are easy to install and offer no major risk or discomfort to the user. Implementation of these technologies into medicine has exponentially grown in the past decade with supporting evidence for their use in cardiovascular disease and sleep medicine. The investigators believe that these devices will be able to capture the changes associated with improvement in non-specific symptoms that have not been previously demonstrated., conditionsModule conditions: Primary Hyperparathyroidism, conditions: Multinodular Goiter, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 80, type: ESTIMATED, armsInterventionsModule interventions name: Activity Tracker (Fitbit), interventions name: HbA1C, interventions name: The PROMPT Questionnaire, outcomesModule primaryOutcomes measure: Change in resting heart rate over time among study participants as monitored by fitness tracker, primaryOutcomes measure: Change in number of awakenings during sleep over time among study participants as monitored by fitness tracker, primaryOutcomes measure: Change in % Deep Sleep over Total Sleep Minutes over time among study participants as monitored by fitness tracker, primaryOutcomes measure: Change in steps over time among study participants as monitored by fitness tracker, primaryOutcomes measure: Change in total active minutes over time among study participants as monitored by fitness tracker, primaryOutcomes measure: Change in% Active Calorie over Total Calories over time among study participants as monitored by fitness tracker, primaryOutcomes measure: Change in glucose levels (HbA1C), primaryOutcomes measure: Correlation of Quality of Life surveys with the PROMPT survey, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: The Cleveland Clinic Foundation, city: Cleveland, state: Ohio, zip: 44195, country: United States, geoPoint lat: 41.4995, lon: -81.69541, hasResults: False
protocolSection identificationModule nctId: NCT06337812, orgStudyIdInfo id: HUM00240473, briefTitle: Fiber Supplementation in Heart Failure With Preserved Ejection Fraction (HFpEF), statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04, primaryCompletionDateStruct date: 2025-06, completionDateStruct date: 2025-06, studyFirstPostDateStruct date: 2024-03-29, lastUpdatePostDateStruct date: 2024-03-29, sponsorCollaboratorsModule leadSponsor name: University of Michigan, class: OTHER, descriptionModule briefSummary: The study team is studying how increasing dietary fiber, specifically through adding potato starch to participant's diet, may impact the species of bacteria in participant's gut microbiome. The study team also wants to understand if adding potato starch to participant's diet helps these bacteria make more short chain fatty acids, a byproduct the team thinks may benefit participant's health., conditionsModule conditions: Type2diabetes, conditions: Heart Failure With Preserved Ejection Fraction, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: HEALTH_SERVICES_RESEARCH, maskingInfo masking: NONE, enrollmentInfo count: 30, type: ESTIMATED, armsInterventionsModule interventions name: Potato Starch, outcomesModule primaryOutcomes measure: Changes in Short Chain Fatty Acid (SCFA) butyrate levels - stool, primaryOutcomes measure: Changes in Short Chain Fatty Acid (SCFA) butyrate levels - plasma, primaryOutcomes measure: Changes in propionate levels - stool, primaryOutcomes measure: Changes in propionate levels- plasma, primaryOutcomes measure: Changes in acetate levels- stool, primaryOutcomes measure: Changes in acetate levels- plasma, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: University of Michigan, city: Ann Arbor, state: Michigan, zip: 48109, country: United States, contacts name: Hayley Billingsley, PhD, role: CONTACT, phone: 734-726-0308, email: hbilings@med.umich.edu, contacts name: Scott Hummel, MD, MS, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 42.27756, lon: -83.74088, hasResults: False